4
Changes in Ownership
CRISPR Therapeutics AG Filed Acc 0001209191-20-062919
Chief Executive Officer sold 20,000 shares at an average $142.29 ($2,845,782)
- Chief Executive Officer acquired 20,000 shares (option exercise)
From the SEC's structured data for this filing
Trades in this filing
| Insider | Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|---|
| Kulkarni Samarth Chief Executive Officer | 2020-12-10 | Option exercise | +20,000 | $1.81 | $36,200 | 189,189 | D |
| Kulkarni Samarth Chief Executive Officer | 2020-12-10 | Sale | −5,500 | $141.17 | $776,435 | 183,689 | D |
| Kulkarni Samarth Chief Executive Officer | 2020-12-10 | Sale | −5,034 | $141.98 | $714,727 | 178,655 | D |
| Kulkarni Samarth Chief Executive Officer | 2020-12-10 | Sale | −6,766 | $142.75 | $965,847 | 171,889 | D |
| Kulkarni Samarth Chief Executive Officer | 2020-12-10 | Sale | −2,100 | $143.71 | $301,791 | 169,789 | D |
| Kulkarni Samarth Chief Executive Officer | 2020-12-10 | Sale | −600 | $144.97 | $86,982 | 169,189 | D |
| Derivatives | |||||||
| Kulkarni Samarth Chief Executive Officer | 2020-12-10 | Option exercise · Stock Option (Right to Buy) | −20,000 | 142,783 | D | ||
| Open-market sales · 20,000 sh · avg $142.29 · $2,845,782 | |||||||
Loading xslF345X03/doc4.xml…